Cantitate/Preț
Produs
Total produse
Vezi coșul
Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer de Michail Ignatiadis

Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer: Recent Results in Cancer Research, cartea 195

Editat de Michail Ignatiadis, Christos Sotiriou, Klaus Pantel
en Limba Engleză Paperback – 9 mai 2014
This important book provides up-to-date information on a series of topical issues relating to the approach to minimal residual disease in breast cancer patients. It first explains how the study of minimal residual disease and circulating and disseminated tumor cells (CTCs/DTCs) can assist in the understanding of breast cancer metastasis. A series of chapters then discuss the various technologies available for the detection and characterization of CTCs and DTCs, pinpointing their merits and limitations. Detailed consideration is given to the relevance of CTCs and DTCs, and their detection, to clinical research and practice. The role of other blood-based biomarkers is also addressed, and the closing chapters debate the challenges facing drug and biomarker co-development and the use of CTCs for companion diagnostic development. This book will be of interest and assistance to all who are engaged in the modern management of breast cancer.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 76181 lei  43-57 zile
  Springer Berlin, Heidelberg – 9 mai 2014 76181 lei  43-57 zile
Hardback (1) 107621 lei  43-57 zile
  Springer Berlin, Heidelberg – 23 apr 2012 107621 lei  43-57 zile

Din seria Recent Results in Cancer Research

  • 5% Cancer Clinical Trials: A Critical Appraisal
    Preț: 30177 lei
  • 5% Regulatory and Economic Aspects in Oncology
    Preț: 82809 lei
  • 5% Tumor Liquid Biopsies
    Preț: 19169 lei
  • 5% Viruses and Human Cancer: From Basic Science to Clinical Prevention
    Preț: 76663 lei
  • 5% Ethical Challenges in Cancer Diagnosis and Therapy
    Preț: 89526 lei
  • 5% Liver Fluke, Opisthorchis viverrini Related Cholangiocarcinoma: Liver Fluke Related Cholangiocarcinoma
    Preț: 90064 lei
  • 5% Current Problems in the Epidemiology of Cancer and Lymphomas: Symposium of the Gesellschaft zur Bekämpfung der Krebskrankheiten, Nordrhein-Westfalen, e. V
    Preț: 39223 lei
  • 15% Die tierische Zelle in Zellkultur
    Preț: 48052 lei
  • 5% Radioactive Phosphorus in the Diagnosis of Gastrointestinal Cancer
    Preț: 68960 lei
  • 5% Therapeutic Strategies in Primary and Metastatic Liver Cancer
    Preț: 70645 lei
  • 5% Locoregional High-Frequency Hyperthermia and Temperature Measurement
    Preț: 69500 lei
  • 5% Epidemiology of Malignant Melanoma
    Preț: 69679 lei
  • 5% Preoperative (Neoadjuvant) Chemotherapy
    Preț: 69623 lei
  • 5% Hyperthermia and the Therapy of Malignant Tumors
    Preț: 69891 lei
  • 5% Breast Cancer: Present Perspective of Early Diagnosis
    Preț: 35453 lei
  • 5% Minimal Neoplasia: Diagnosis and Therapy
    Preț: 69820 lei
  • 5% Application of Hyperthermia in the Treatment of Cancer
    Preț: 36365 lei
  • 5% Supportive Care in Cancer Patients
    Preț: 70735 lei
  • 5% Preclinical Hyperthermia
    Preț: 70235 lei
  • 5% Treatment of Skin Cancer
    Preț: 34916 lei
  • 5% Combined Modality Therapy of Gastrointestinal Tract Cancer
    Preț: 70519 lei
  • 5% AIDS-Related Neoplasias
    Preț: 35240 lei
  • 5% Endocrine Therapy and Growth Regulation of Breast Cancer
    Preț: 69213 lei
  • 5% Cancer Mapping
    Preț: 70322 lei
  • 5% Adjuvant Therapy of Primary Breast Cancer
    Preț: 70463 lei
  • 5% Bisphosphonates and Tumor Osteolysis
    Preț: 69107 lei
  • 5% New Aspects in the Diagnosis and Treatment of Hodgkin’s Disease: First International Symposium on Hodgkin's Lymphoma in Cologne, October 2-3, 1987
    Preț: 70377 lei
  • 5% Hormone-Related Malignant Tumors
    Preț: 70271 lei
  • 5% Advances in Breast Cancer Detection
    Preț: 69679 lei
  • 5% Hereditary Factors in Carcinoma
    Preț: 69785 lei
  • 5% Occupational Cancer Epidemiology
    Preț: 69658 lei
  • 5% Supportive Care in Cancer Patients II
    Preț: 37134 lei
  • 5% Pathobiology of Human Germ Cell Neoplasia
    Preț: 106762 lei
  • 5% Peptides in Oncology I: LH-RH Agonists and Antagonists
    Preț: 35382 lei
  • 5% Medullary Thyroid Carcinoma
    Preț: 69785 lei
  • 5% Malignancies of the Genitourinary Tract
    Preț: 70110 lei
  • 5% Adjuvant Therapy of Breast Cancer IV
    Preț: 70235 lei
  • 5% Skin Carcinogenesis in Man and in Experimental Models
    Preț: 70610 lei
  • 5% Peptides in Oncology II: Somatostatin Analogues and Bombesin Antagonists
    Preț: 69356 lei
  • 5% Tumours in Children
    Preț: 71719 lei
  • 5% Acute and Long-Term Side-Effects of Radiotherapy: Biological Basis and Clinical Relevance
    Preț: 70144 lei
  • 5% Recent Advances in Cell Biology of Acute Leukemia: Impact on Clinical Diagnosis and Therapy
    Preț: 70844 lei
  • 5% Infectious Complications in Bone Marrow Transplantation
    Preț: 36168 lei
  • 5% Current Status of Diagnostic Cytology
    Preț: 69500 lei
  • 5% Carcinoma of the Oral Cavity and Oropharynx
    Preț: 69820 lei
  • 5% Molecular Neuro-oncology and Its Impact on the Clinical Management of Brain Tumors
    Preț: 69715 lei
  • 5% Familial and Hereditary Tumors
    Preț: 70483 lei
  • 5% Hypercalcemia of Malignancy
    Preț: 69481 lei
  • 5% Soft Tissue Sarcomas in Adults
    Preț: 69572 lei
  • 5% Skin Cancer: Basic Science, Clinical Research and Treatment
    Preț: 71006 lei

Preț: 76181 lei

Preț vechi: 80191 lei
-5% Nou

Puncte Express: 1143
Preț estimativ în valută:
14579€ • 15144$ • 12110£

Carte tipărită la comandă

Livrare economică 03-17 februarie 25

 Adaugă în coș

Wish list
Gift list
Am citit!
Adaugă în listă
Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783642445873
ISBN-10: 364244587X
Pagini: 268
Ilustrații: XIV, 254 p.
Dimensiuni: 155 x 235 x 14 mm
Greutate: 0.39 kg
Ediția:2012
Editura: Springer Berlin, Heidelberg
Colecția Springer
Seria Recent Results in Cancer Research

Locul publicării:Berlin, Heidelberg, Germany

Public țintă

Professional/practitioner

Cuprins

Minimal residual disease and circulating tumor cells in breast cancer: Open questions for research.- Minimal residual disease and breast cancer metastasis.- Self-seeding in cancer.- Microenvironments dictating tumor cell dormancy.- Technologies for circulating tumor cell (CTC) and disseminated tumor cell (DTC) detection and characterization.- Immunomagnetic separation technologies.- Microfluidic technologies for the isolation of CTCs.- EPISPOT assay: Detection of viable disseminating tumor cells in solid tumor patients.- Advances in optical technologies for rare cell detection and characterization.- Size-based enrichment technologies for circulating tumor cell (CTC) detection and characterization.- Emerging technologies for CTC detection based on depletion of normal cells.- Molecular assays for the detection and characterization of CTCs.- Multiplex molecular analysis of CTCs.- Other blood-based biomarkers.- Circulating DNA and next generation sequencing.- Circulating microRNAs as non-invasive biomarkers in breast cancer.- Circulating endothelial cells and circulating endothelial progenitors.- Disseminated tumor cells (DTCs) and circulating tumor cells (CTCs) in breast cancer clinical research and practice.- Bone marrow DTCs.- CTCs in primary breast cancer.- CTCs in early breast cancer.- CTCs in metastatic breast cancer.- HER2-positive DTCs/CTCs in breast cancer.- DTCs and CTCs in breast cancer – 5 decades later.- Drug and circulating tumor cell co-development.- Challenges in drug and biomarker co-development.- Challenges and opportunities in the use of CTCs for companion diagnostic development.

Textul de pe ultima copertă

Most deaths from carcinomas are caused by the hematogenous dissemination of cancer cells to distant organs and the eventual development of metastases. When found in the bone marrow or peripheral blood of carcinoma patients, occult cancer cells are referred to as disseminated tumor cells (DTCs) or circulating tumor cells (CTCs). CTCs and DTCs are considered surrogates of minimal residual disease, i.e., the presence of malignant cells in distant organs that are undetectable by conventional imaging and laboratory tests used for tumor staging after curative surgery of the primary tumor.
 
In this book, leading investigators in the field provide up-to-date information on a series of important questions, including:
 
-  How can the study of minimal residual disease and CTCs help us to better understand breast cancer metastasis?
-  What technologies are available for the detection and characterization of CTCs and DTCs, and what are their relative merits?
-  How are DTCs and CTCs relevant to clinical research and practice?
- What is the role of other blood-based biomarkers such as circulating endothelial cells and circulating nucleic acids?
-  What are the challenges in drug and biomarker co-development and the use of CTCs for companion diagnostic development?
 
This book will be of interest and assistance to all who are engaged in the modern management of breast cancer.

Caracteristici

Provides up-to-date information on topical issues concerning minimal residual disease in breast cancer patients Appraises the technologies available for detection and characterization of circulating and disseminated tumor cells (CTCs/DTCs) Discusses the relevance of CTCs and DTCs in breast cancer clinical research and practice, and the role of other blood-based biomarkers Includes supplementary material: sn.pub/extras